- Clinical Trials
- March 2025
- 60 Pages
Global
From €1195EUR$1,250USD£1,000GBP
- Report
- June 2024
- 200 Pages
Global
From €7601EUR$7,950USD£6,363GBP
- Report
- January 2022
- 60 Pages
Global
From €3777EUR$3,950USD£3,161GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1912EUR$2,000USD£1,601GBP
- Report
- April 2023
- 147 Pages
Global
From €4732EUR$4,949USD£3,961GBP
- Report
- July 2023
- 82 Pages
Global
From €3500EUR$3,921USD£3,032GBP
Polyneuropathy is a type of neurological disorder that affects multiple peripheral nerves, leading to numbness, weakness, and pain in the hands and feet. It is a common complication of diabetes, and can also be caused by autoimmune diseases, infections, and other conditions. Treatment for polyneuropathy typically involves medications to reduce pain and improve nerve function.
Central nervous system (CNS) drugs are used to treat a variety of neurological disorders, including polyneuropathy. These drugs can be divided into two categories: analgesics, which are used to reduce pain, and neuroprotective agents, which are used to protect nerve cells from damage. Commonly prescribed CNS drugs for polyneuropathy include anticonvulsants, antidepressants, and antispasmodics.
Several companies are involved in the polyneuropathy drug market, including Pfizer, GlaxoSmithKline, Merck, and Novartis. These companies produce a variety of CNS drugs for the treatment of polyneuropathy, including pregabalin, duloxetine, and gabapentin. Show Less Read more